Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | KISS1R | Q969F8 | 10/20 | 0.57 |
| ▸ | IL1RN | P18510 | 1/20 | 0.56 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | GHSR | Q92847 | 1/20 | 0.55 |
| ▸ | CCKAR | P32238 | 1/20 | 0.55 |
| ▸ | CCKBR | P32239 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31488633 | 0.90 | KISS1R (0.66) | KISS1RIL1RNERAP2 | |
| SCHEMBL30122986 | 0.89 | KISS1R (0.61) | OPRD1OPRM1KISS1R | |
| SCHEMBL30418018 | 0.89 | OPRM1 (0.59) | OPRD1OPRM1KISS1RERAP2NPY1R | |
| SCHEMBL30522299 | 0.89 | ERAP2 (0.62) | OPRD1OPRM1IL1RNERAP2NPY1R | |
| SCHEMBL30799826 | 0.89 | GHSR (0.57) | OPRD1OPRM1GHSRCCKARCCKBR | |
| SCHEMBL29425581 | 0.89 | KISS1R (0.59) | OPRD1OPRM1KISS1R | |
| SCHEMBL30845363 | 0.88 | KISS1R (0.68) | KISS1RIL1RNERAP2 | |
| SCHEMBL31575718 | 0.88 | OPRM1 (0.58) | OPRD1OPRM1KISS1RIL1RNERAP2 | |
| SCHEMBL31196546 | 0.87 | OPRM1 (0.59) | OPRD1OPRM1KISS1RIL1RNERAP2 | |
| SCHEMBL29425599 | 0.87 | KISS1R (0.57) | OPRD1OPRM1KISS1RCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630620-B2 | Anti-GDF15 neutralizing monoclonal antibody and use thereof | NUAGE (SHAANXI) MEDICAL AND TECHNOLOGY COMPANY LTD (CN) | 2026-05-19 | — | — | US | claimed |
| US-20230203145-A1 | ANTI-GDF15 NEUTRALIZING MONOCLONAL ANTIBODY AND USE THEREOF | NUAGE (SHAANXI) MEDICAL AND TECHNOLOGY COMPANY LTD (CN) | 2023-06-29 | — | — | US | claimed |
| CN-111393526-B | anti-GDF 15 neutralizing monoclonal antibody and application thereof | 中国人民解放军第四军医大学 | 2022-04-12 | — | — | CN | claimed |
| US-12630620-B2 | Anti-GDF15 neutralizing monoclonal antibody and use thereof | NUAGE (SHAANXI) MEDICAL AND TECHNOLOGY COMPANY LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20230203145-A1 | ANTI-GDF15 NEUTRALIZING MONOCLONAL ANTIBODY AND USE THEREOF | NUAGE (SHAANXI) MEDICAL AND TECHNOLOGY COMPANY LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-114560938-B | Neutralizing monoclonal antibody against GDF15 and application thereof | 中国人民解放军第四军医大学 | 2023-05-23 | — | — | CN | disclosed |
| CN-114560938-A | anti-GDF 15 neutralizing monoclonal antibody and application thereof | 中国人民解放军第四军医大学 | 2022-05-31 | — | — | CN | disclosed |
| CN-111393526-B | anti-GDF 15 neutralizing monoclonal antibody and application thereof | 中国人民解放军第四军医大学 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630620-B2 | Anti-GDF15 neutralizing monoclonal antibody and use thereof | ARGLU1, ARG1, ISG15 | OPRD1 1347/4885OPRM1 948/4885KISS1R 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.